Thursday, 15 October 2020

Lorianne Shultz Awarded 2020 NWRI-BioLargo Graduate Fellowship

For many years, BioLargo has sponsored fellowships offered by the National Water Research Institute (NWRI) to graduate students in the US who focus on cutting-edge water research. This $5,000 fellowship recognizes students who research the technical and scientific aspects of advanced water and wastewater treatment.

This year, we are happy to announce that the NWRI-BioLargo Graduate Fellowship has been awarded to Lorianne Shultz, a PhD student at the University of Central Florida. Shultz’s research project, which she is completing in the laboratory of Dr. Titel Jurca, is called “Chlorine Stable Heterogeneous Catalysts for the Remediation of Stubborn Water Pollutants”.

Lorianne Shultz, NWRI-
BioLargo Fellowship winner

Lorianne explained to us the importance of her research, “Pharmaceuticals and personal care products are accumulating in our waterways at alarming rates; this is especially true with the world’s growing population. This issue can be remediated through heterogenous catalytic degradation of these pollutants, a methodology that I believe is commonly overlooked in the water-industry. I was thrilled to receive this fellowship as it helps validate the use of catalytic materials for water-remediation and these funds help me expand this field of research further. I am excited to be working in connection with BioLargo, a company so dedicated to this field and at the forefront of improvement for water treatment systems.”

Dennis P. Calvert, President & CEO of BioLargo, commented, “Shultz’s research goals align well with NWRI’s mission to protect and improve water management in the US, and they also align with BioLargo’s vision of seeking innovative new methods of addressing tough contaminants that threaten the health and safety of people around the world. We are thrilled to sponsor her work, and we are excited to learn from her research.”

NWRI is a 501c3 nonprofit that collaborates with water utilities, regulators, and researchers in innovative ways to help develop new, healthy sources of drinking water. To learn more about NWRI’s graduate fellowship program, go to the NWRI website: https://www.nwri-usa.org/fellowships.

Wednesday, 14 October 2020

Clyraguard Personal Protection Spray Now Available On Amazon.Com For Consumers Nationwide

BioLargo subsidiary Clyra Medical Technologies Joins Forces with Powerplay Retail to Ensure

Broad Availability of Revolutionary Product to Safeguard Against Airborne Viruses

Westminster, CA – October 14, 2020 – Just in time for Amazon Prime Day, BioLargo, Inc. (OTCQB:BLGO), developer of sustainable life science technologies, today announced that Clyraguard, the personal disinfectant and germicidal spray that safely and easily decontaminates masks and face coverings, is now available at the Clyra Medical Store on Amazon.com. Clyraguard is manufactured by BioLargo’s subsidiary Clyra Medical Technologies, a med-tech company with deep experience fighting hospital-acquired infections with innovative technologies.

In addition, Clyra Medical announced a partnership with Powerplay Retail, an agency and distributor that has helped launch some of the best-known consumer products in the world, to roll-out Clyraguard to major retailers nationwide. Powerplay Retail brings to bear relationships with some of the world’s biggest online and in-store retailers, including more than 80 of the largest, most recognizable retailers in the United States.

BioLargo President & CEO Dennis Calvert commented, “We have assembled an exceptional team to execute a multi-phase roll out plan for Clyraguard. This Amazon launch, in partnership with Powerplay Retail, is another important step toward maximizing consumer access to this valuable product.”

“As we continue to battle this unprecedented pandemic, Clyraguard provides an embedded layer of iodine on one’s mask or face covering for additional protection against unwanted pathogens, including the SARS-CoV-2 virus, without having to remove your mask,” said Steve Harrison, CEO, Clyra Medical Technologies. “Until now, this hospital-grade disinfectant was available only to healthcare professionals. Making Clyraguard available on Amazon.com, as well as partnering with Powerplay Retail, ensures we can deliver a much-needed solution to consumers nationwide.”

Clyraguard has shown complete inactivation of SARS-CoV-2 (COVID-19), according to recent testing at University of Texas Medical Branch at Galveston, and is based on Clyra Medical’s original advanced wound care technology, which received 510(k) clearance from the Food and Drug Administration (FDA).  Clyraguard is a hospital-grade, FDA-registered disinfectant that is specifically indicated for PPE, like masks and face coverings.

“At Powerplay our goal is to help our retail partners find the right brands and the right technologies while weeding out the noise in this increasingly competitive marketspace,” said Tracy Thie, Principal, Co-Founder Powerplay Retail.  “As health and safety have become a core part of our daily lives, we have made it a point to help support our retail partners to bring the right health & wellness products to the masses. Our partnership with Clyra creates a great opportunity to bring Clyraguard to market at a time when people want and need this product.”

Clyraguard has been rigorously tested and proven to be safe and long-lasting, providing an extremely high 99.999% antimicrobial efficacy against viruses, bacteria and fungi.  Gentle and safe, its eco-friendly ingredients are mineral-based, alcohol-free, non-toxic, non-irritating and non-sensitizing.

Available in 4 oz. spray bottle, the personal protection spray is small enough for a purse or pocket yet contains two months of supply with typical usage, and for travelers, Clyraguard classifies under current TSA hand sanitizer exemptions. Clyraguard is now available to consumers online at www.clyramedical.com, the Clyra Medical Store on Amazon.com, and soon to be available at retailers nationwide.

 

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About Clyra Medical Technologies

Clyra Medical Technologies, is a subsidiary of BioLargo, Inc. (OTCQB:BLGO), a sustainable science, technology and full-service environmental engineering company that makes life better by delivering world-class products and services across a broad range of industries, with a drive to deliver solutions in clean water and wastewater treatment, clean air and air quality control, and advanced antimicrobials for healthcare. 

About Powerplay Retail

Powerplay Retail is a privately held, Minnesota based company with offices in Bentonville, Arkansas, and Shenzhen China. With over 250 years of combined retail experience bringing brands like Beats by Dr. Dre and GoPro to consumers they continue to vet and identify new retail opportunities to best serve their brand and retail partners. For more information on Powerplay Retail, visit powerplayretail.com.

Contact

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

 

Thursday, 8 October 2020

BioLargo Breaks Revenue Records in Third Quarter of 2020

Clyraguard manufacturing and distribution through national partners begins

Westminster, CA – October 8, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and full-service environmental engineering company, today provided highlights of its results and activities from the third quarter of 2020.

BioLargo President & CEO Dennis P. Calvert commented, “With our subsidiary Clyra Medical Technologies having successfully executed the first phase of the Clyraguard product launch, this quarter set new records for BioLargo, and we expect the next quarter to be even stronger for the company and Clyraguard. We have made a significant investment in building our supply chain capabilities, organizing our marketing team, and dedicated business development efforts, and we expect future periods to continue to improve.”  

Financial highlights:

·       BioLargo achieved record company-wide revenue. Revenues for the period ended September 30, 2020 were approximately $650,000, representing about a 60% increase compared to the $418,000 generated in the second quarter of 2020.  Revenues for the nine months ended September 30, 2020 were approximately $1,600,000, about a 20% increase compared to the $1,324,000 generated in the nine months ended September 30, 2019.

·       Substantial improvements to the company’s balance sheet, with $3,553,000 of debt being converted to equity by the company since December 31, 2019.

Highlights for BioLargo’s subsidiaries:

Clyra Medical Technologies

·       Clyra is executing on its comprehensive roll out plan for Clyraguard Personal Protective Spray, having overcome early challenges developing a robust manufacturing and supply chain during Covid. New manufacturing relationships support capacity of up to 1,000,000 Clyraguard units per month, and ample supply has been placed with distributors across the country.

·       Sales channels launching now include the largest distributors to the healthcare and restaurant industries, Amazon.com, a revamped Clyraguard website (www.Clyraguard.com), and multiple online resellers, with a retail unit price of $25 per bottle.

·       The Clyraguard launch is supported by new company additions – Shawn Dougherty (Mophie founder), Johnny Sirpilla (former President of Camping World), and new agreements with a national marketing and public relations firm, and national sales organization, to be announced soon.

BioLargo Engineering, Science & Technologies

·       Multiple projects are being finalized with two major municipal public water agencies for the company’s PFAS treatment technology (the BioLargo AEC).

·       Developed a proprietary and patent-pending process to extract valuable mineral resources from a large industrial waste site. As a consequence of this new process, a client is planning a substantial long-term project expected to generate over $1B in revenues for the project. As the client’s engineering services provider, and developer of the technology, BioLargo Engineering is in discussions with the client to secure its role as the project manager and/or lead engineer.

·       Secured a client contract for a project to use regenerative thermal oxidation for air quality control (a particular expertise of some of our engineers), which is expected to generate $500,000 in revenue for BioLargo Engineering through 2021.  

·       BioLargo Engineering now has contracts in place for approximately $1,000,000 in revenue, which is expected to be realized between now through the end of 2021.

ONM Environmental

·       Revenues in the third quarter of 2020 began to rebound from their pandemic-related dip to approximately $350,000.

·       With nearly $400,000 in construction business already secured for the fourth quarter of 2020,  management expects the fourth quarter 2020 to be a new high record for revenue at ONM Environmental.

·       Cannabusters (ONM Environmental’s white label partner for the cannabis industry) is gaining traction in the market, resulting in 12 equipment installations for ONM Environmental so far, with another three contracted for the fourth quarter 2020.

BioLargo Water

·       BioLargo Water’s first commercial project for its AOS water treatment technology, wherein the first for-profit installation of an AOS will take place at a poultry farm, is moving forward as planned, and which is expected to generate more than $500,000 in revenue over the next year.

·       Our engineers are building the AOS unit to be installed at the wastewater treatment facility near Montreal, Quebec, for the demonstration pilot to be run in partnership with acclaimed water experts at the Centre des Technologies de L’Eau (CTE).

·       BioLargo Water secured Health Canada approval for two hand sanitizer product formulations and a license to manufacture and sell these products (one of which incorporates CupriDyne technology), to serve its local community.  

·       Developed and executed crucial EPA-approved protocols to produce data to support the efficacy of a CupriDyne technology-related disinfectant in preparation for an EPA application for a hard-surface disinfectant and sanitizer, in support of BioLargo’s efforts to secure EPA registration.

 

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard (www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

During the course of the stockholder presentation, BioLargo may make “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, regarding future events or the future financial performance of the company that are subject to change. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Sunday, 20 September 2020

BioLargo Wins Octane HTA Award for COVID-19 Response

Over the past few months, BioLargo pivoted to develop and deliver solutions to help combat the COVID-19 pandemic, including Clyraguard Personal Protection Spray, manufactured and sold by our subsidiary Clyra Medical Technologies. At the outset of the pandemic, we recognized that our iodine-based technologies would make a meaningful contribution to the fight against SARS-CoV-2 (the virus that causes COVID-19). Our response is directly in line with our mission statement to “make life better” because nothing is more important right now than helping protect people against this virus.

Last week at the 27th Octane High Tech Awards, BioLargo was honored for its contribution to the fight against COVID with a “COVID-19 Response Recognition Award”. We thank the Octane team for this honor, and we are humbled to have been recognized among such incredible Orange County based innovators.

The award highlighted BioLargo’s agile response to COVID. They noted that the company’s subsidiary Clyra Medical Technologies worked quickly to roll out Clyraguard Personal Protection Spray (www.clyramedical.com/clyraguard), which recently launched to great enthusiasm, with sales and distribution presently ramping up through national partners.

Clyraguard, an FDA-registered hospital-grade disinfectant, offers an additional line of defense against COVID-19. It helps protects mask-wearers from cross contamination by providing quick, safe, effective on-the-go decontamination of masks and other noncritical PPE. It has been tested and proven effective to completely inactivate SARS-CoV-2 (COVID-19) in a published study conducted by Galveston National Lab (UTMB-Galveston), and it is proven to be non-toxic, non-irritating, non-sensitizing, safe on skin, and eco-friendly.

Launching this product was no easy task – Clyra set up contract manufacturing capable of delivering up to 1 million units per month, secured FDA registration, built a full-scale marketing campaign that is currently launching, and established partnerships with national distributors.

BioLargo also advanced its proprietary iodine technology to be used as an environmental disinfectant. Already, third-party studies were conducted that proved the product, derived from BioLargo’s CupriDyne® technology, achieving complete inactivation against SARS-CoV-2 in only 10 minutes.

This award is not the first time that BioLargo has been honored by Octane at their HTA event. In 2017, BioLargo received an Octane award for Horizontal Disruption because of the company’s diverse innovative life sciences technologies. The following year, BioLargo CEO Dennis P. Calvert was invited to be a judge for the 2018 HTA awards alongside decorated entrepreneur Shawn Dougherty (who is now Clyra Medical Technologies’ Chief Revenue Officer). We believe organizations like Octane, which is Orange County's premier tech incubator, are crucial in times like these, as they promote the advancement of critically important innovative technologies that help make people’s lives better.

On a Clyraguard-related note – we are anxious to update everyone on the advancement of Clyraguard sales, so keep an eye out for more Clyraguard news!

Wednesday, 2 September 2020

BioLargo’s CupriDyne Technology Shown Capable of Complete SARS-CoV-2 Inactivation in 10 Minutes

Westminster, CA – September 2, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, today announced an important milestone in its ongoing efforts to bring to market a safe and effective antiviral disinfectant based on its patented CupriDyne® technology. In a third-party study conducted by researchers at the Galveston National Laboratory (GNL) at the University of Texas Medical Branch (UTMB), a modified CupriDyne formula was shown to cause complete inactivation of SARS-CoV-2 (the COVID-19 virus) in 10 minutes – roughly the same performance observed with highly concentrated bleach.

BioLargo had previously disclosed that its CupriDyne technology was proven capable of reducing SARS-CoV-2 titers by 99% after 30 minutes, with complete inactivation occurring after 60 minutes of CupriDyne exposure. Since that time, BioLargo scientists worked to modify the CupriDyne formula to achieve faster bacterial and viral inactivation in order to prepare to file for an EPA registration for a new disinfecting product (to be named) that is based on the CupriDyne technology. These new results indicate that those efforts were successful, and that the technology is now capable of total antiviral disinfection in 10 minutes against SARS-CoV-2.

BioLargo President & CEO Dennis P. Calvert commented, “We believe that the future is bright for our CupriDyne-based disinfectants. We intend to apply for registration with the EPA once product designs are finalized.  It is important to understand that we are achieving these extraordinary results at a significantly lower concentration than that of bleach in the same test protocol. We have retained a leading EPA consulting firm to lead us in the EPA registration process and intend to move ahead as soon as possible. These products are a great addition to our expanding portfolio.”

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About Galveston National Laboratory/UTMB

The Galveston National Laboratory (GNL) is a sophisticated high containment research facility that serves as a critically important resource in the global fight against infectious diseases. The GNL is located on the campus of the University of Texas Medical Branch and operates under the umbrella of UTMB’s Institute for Human Infections and Immunity.

Researchers at the GNL are internationally known for their expertise working with pathogens including Ebola and Marburg, emerging infectious diseases like MERS, and mosquito borne viruses like Zika and Chikungunya. The Galveston National Laboratory is home to research that is funded by NIAID, the U.S. Department of Defense, the U.S. Centers for Disease Control & Prevention and other federal agencies, as well as academic partners, private foundations, and the Biopharmaceutical industry.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

During the course of the stockholder presentation, BioLargo may make “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, regarding future events or the future financial performance of the company that are subject to change. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.


Tuesday, 25 August 2020

BioLargo to Present at The LD 500 Virtual Conference

LOS ANGELES, CA / ACCESSWIRE / August 25, 2020 / BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, today announced that it will be presenting at the LD 500 Investor Conference on Tuesday, September 1, 2020 at 8:00 AM PST / 11:00 AM EST. BioLargo President & CEO Dennis P. Calvert will be presenting to a live virtual audience of prospective investors.

A major focus of Mr. Calvert’s presentation will be Clyraguard Personal Protection Spray. BioLargo’s subsidiary Clyra Medical Technologies recently launched Clyraguard, a safe, effective, FDA-registered disinfectant for use on personal protection equipment (PPE) like facemasks. The company is currently ramping up distribution and sales of the new product through agreements with several contract manufacturers and a major national healthcare products distributor.

Mr. Calvert will also discuss the company’s per- and polyfluoroalkyl substance (PFAS) treatment technology, the BioLargo AEC, which is expected to begin its first pilots and commercial trials in late 2020 and early 2021. PFAS are a persistent and widespread class of contaminants of emerging concern globally due to their ability to cause serious health problems in humans and because of the difficulty with which they are removed from water. The BioLargo AEC has been proven capable of 99%+ PFAS removal from water in continuous flow and expects to be a low cost high efficiency solution for industry.

Register here: https://ld500.ldmicro.com/

"We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space.” stated Chris Lahiji, Founder of LD Micro.

The LD 500 will take place on September 1st through the 4th.

View BioLargo’s profile here: http://www.ldmicro.com/profile/BLGO


Profiles powered by LD Micro — News Compliments of Accesswire

 

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective against viruses and bacteria, and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About LD Micro

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.

What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.

The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contact:

Name: Dennis P. Calvert

Phone: 888-400-2863

Email: dennis.calvert@biolargo.com

Source: BioLargo, Inc. via LD Micro

 

BioLargo Announces Municipal Wastewater Treatment Pilot

Westminster, CA – August 25, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, announced today that its first municipal wastewater treatment demonstration pilot of its AOS and AEC water treatment technologies will take place at a wastewater treatment plant near Montréal, Québec. Experts in water treatment and technology development from the Centre des Technologies de L’Eau (CTE) will supervise and validate the performance of the pilot on-site.

The purpose of the pilot is to assess BioLargo’s proprietary water treatment technologies – the Advanced Oxidation System (AOS) and Aqueous Electrostatic Concentrator (AEC) – as effective, cost-efficient, and complementary solutions for disinfecting and eliminating a broad range of recalcitrant contaminants from municipal wastewater in an operating wastewater treatment plant. The AOS and AEC have previously been shown to effectively remove hard-to-treat contaminants such as pharmaceutical pollutants, as well as other micropollutants like per- and poly-fluoroalkyl substances (PFAS), respectively.

This new pilot comes shortly after the successful conclusion of the company’s first demonstration pilot for the AOS technology at a poultry farm and processing facility near Edmonton, Alberta, where the technology was proven capable of providing effective and affordable treatment of poultry wastewater to the U.S. EPA’s safe water discharge standards. In keeping with BioLargo’s business plan, the company next sought to demonstrate the technology in a municipal wastewater treatment application.

The joint AOS/AEC demonstration pilot is funded in part by the Canadian Natural Science and Engineering Research Council (NSERC), through an Applied Research and Development (ARD) program grant, which will provide $225,000 CAD for the project. BioLargo’s engineers and scientists are building the AOS and AEC units for the pilot, and hope to have them installed and running by the end of October. Because of the pilot’s scope, the company expects to report initial results in the first quarter of 2021.

BioLargo Water President Dr. Richard Smith commented. “This is an extremely exciting pilot for us. The BioLargo AOS and AEC technologies have the potential to provide myriad benefits to municipal wastewater treatment operators, including reducing operating costs, greater breadth of treatment capabilities, and greater energy efficiency.”

The CTE is a recognized college research center for technology transfer attached to the college of Saint-Laurent in Montreal, Quebec. The mission of CTE is to carry out applied research and development activities, technical assistance, and information dissemination in the field of water technologies. The pilot project is led by the CTE researcher Dr. Rimeh Daghrir, expert in the development of advanced electrochemical technology and the remediation of micro-pollutants from water.

Dr. Daghrir commented, “We are very excited to help move the AOS program along to commercialization. These pilot assays will generate real-time data to show the AOS performance in a real wastewater stream. This AOS innovative technology developed by BioLargo Water is positioned in the water treatment market as an effective and cost-efficient tool for the disinfection and the decontamination of persistent organic pollutants such as the residual of pharmaceutical products. Certainly, this advanced pilot combining AOS technology to AEC system offers an innovative and sustainable solution to problems of water conservation and high cost of industrial water use because it is an extremely powerful, safe, and cost-effective water treatment platform. Thanks to this successful collaboration with BioLargo, funded by NSERC, we have succeeded in training highly qualified experts and graduating students from the Department of Water Technology of the College Saint-Laurent in the environmental electro-technology field.”

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

During the course of the stockholder presentation, BioLargo may make “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, regarding future events or the future financial performance of the company that are subject to change. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.